What We're Reading: Page 83
Industry reads hand-picked by our editors
Nov 21, 2023
-
Reuters
Researchers return to Alzheimer’s vaccines, buoyed by recent drug success
-
FirstWord Pharma
MorphoSys pins hopes on “totality of data” for pelabresib in myelofibrosis
-
The Wall Street Journal
Foot Locker, Teamsters Show Their Drug-Benefit Managers the Door
-
Science
As scientists face a flood of papers, AI developers aim to help
Nov 20, 2023
Nov 17, 2023
-
Investor’s Business Daily
Biotech Stocks: The Race For An Alzheimer’s Cure Takes Off
-
ScienceNews
Why a popular breast cancer drug may be less effective for some Africans
-
Reuters
Manufacturer Lonza says it will not fill obesity drug syringes
Nov 16, 2023
-
Fierce Pharma
Novo Nordisk fights back at Lilly with Wegovy combo trial against Zepbound in obesity
-
Stat
FDA’s latest reorganization puts a new emphasis on its investigations
-
Bloomberg
Sanofi Taps Adviser for OTC Spinoff as Buyout Firms Circle
-
The Boston Globe
The ‘bump factor’ returns to Kendall Square
Nov 15, 2023
-
Reuters
Drugmaker Mallinckrodt emerges from bankruptcy
-
The Boston Globe
EMD Serono plans to join biopharma cluster in Boston’s Seaport
-
KFF Health News
Biden Administration’s Limit on Drug Industry Middlemen Backfires, Pharmacists Say
-
NPR
Roland Pattillo protected Henrietta Lacks’ memory. He died leaving that legacy
Nov 14, 2023
-
Health Affairs
What’s The Worst That Could Happen? A Toothless FDA
-
Fierce Biotech
Hepatitis B drug developers chart slow progress, just like in hep C
-
Regulatory Focus
FDA announces OPQ reorganization to alleviate ‘long-standing pain points’
-
The Transmitter
Making cancer nervous
Previous
